<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00895440</url>
  </required_header>
  <id_info>
    <org_study_id>Neuropad01</org_study_id>
    <nct_id>NCT00895440</nct_id>
  </id_info>
  <brief_title>Role of Indicator Test (Neuropad) in Detecting Diabetic Neuropathy</brief_title>
  <official_title>Neuropad Test for Detection of Sudomotor Dysfunction in Patients With Painful and Painless Diabetic Neuropathy and Charcot Neuroarthropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tameside Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tameside Hospital NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes mellitus can result in damage to the nerves supplying the feet. Various tests can be&#xD;
      used to assess nerve damage but no tests so far have been used to assess loss of sweating&#xD;
      which can lead to dry skin, fissuring and ulceration. The indicator test (Neuropad) is a&#xD;
      plaster which is applied to the sole of the feet just below the 1st and 2nd toes of both&#xD;
      feet. If the color of the plaster changes to pink it indicates that there is no nerve damage&#xD;
      to the nerves. However if the plaster retains the blue color or the color only partially&#xD;
      changes to pink after 600 seconds then this is a positive test and the patient has nerve&#xD;
      damage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With increasing nervous dysfunction, the function of the sweat glands in the feet also&#xD;
      diminishes and can cease completely. As a result the skin becomes brittle and dry, making it&#xD;
      more susceptible to fissuring and breakdown leading to foot ulceration. This is where the&#xD;
      diagnosis using the Neuropad plaster might be useful. The Neuropad measures sweat production&#xD;
      and have been proposed as a new test of neuropathy (8,9). The Neuropad examines the function&#xD;
      of the sweat glands by means of a colour indicator. The indicator test enables the diagnosis&#xD;
      of neuropathy in a substantial proportion of patients with normal clinical examination (10).&#xD;
&#xD;
      This colour indicator, a cobalt-II-salt, is applied in the form of a plaster to the area of&#xD;
      skin on the patient's foot to be examined. In healthy subjects, the moisture (sweat) on the&#xD;
      foot changes the colour of the Neuropad plaster from blue to pink normally within minutes.&#xD;
      However, if the colour does not change completely or very slowly, this indicates initial&#xD;
      nerve damage. This test is, as yet, the only one that examines changes in moistness of the&#xD;
      foot. The speed and scale of the colour change of the Neuropad plaster can then be assessed&#xD;
      as indicators of sudomotor function and thus as indicators of diabetic neuropathy as well.&#xD;
      Although the test has been done in patients with diabetic neuropathy it has not been used as&#xD;
      a discriminator in painless and painful neuropathy, or in patients with Charcot&#xD;
      neuroarthropathy.&#xD;
&#xD;
      In this study we aim to assess the presence of sudomotor dysfunction in patients with painful&#xD;
      and painless neuropathy and patients with Charcot foot.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identify patients with peripheral neuropathy with the Neuropad indicator test</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">139</enrollment>
  <condition>Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Diabetic patients without neuropathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Diabetic patients with painless neuropathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Diabetic patients with painful neuropathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>Diabetic patients with Charcot neuroarthropathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <description>Control non-diabetic subjects</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Type 1 and type 2 diabetic patients with and without peripheral neuropathy (painless and&#xD;
        painful) and Charcot neuroarthropathy; and non-diabetic subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Type 1 or type 2 diabetes&#xD;
&#xD;
          2. Age 18-70 years&#xD;
&#xD;
          3. Presence of painless neuropathy&#xD;
&#xD;
          4. Presence of painful neuropathy&#xD;
&#xD;
          5. Presence of Charcot foot&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with allergy to any metal&#xD;
&#xD;
          2. Peripheral vascular disease (defined as the absence of two or more foot pulses and an&#xD;
             ankle brachial index of &lt; 0.8)&#xD;
&#xD;
          3. Renal failure (serum creatinine &gt; 130 micromol/l)&#xD;
&#xD;
          4. Foot ulceration or cellulitis or osteomyelitis&#xD;
&#xD;
          5. Patients taking drugs that affect sweating (corticosteroids, antihistamines,&#xD;
             psychoactive drugs)&#xD;
&#xD;
          6. Chronic alcohol abuse&#xD;
&#xD;
          7. B12 deficiency (presence of anaemia, raised mean corpuscular volume, past history of&#xD;
             abnormal B12 levels, treatment with B12)&#xD;
&#xD;
          8. Patients with any skin conditions affecting their feet(neurodermatitis, psoriasis,&#xD;
             scleroderma, Raynaud syndrome, hyperhydrosis, acrocyanosis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Jude, MD, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tameside General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tameside General Hospital</name>
      <address>
        <city>Ashton-under-Lyne</city>
        <state>Lancashire</state>
        <zip>OL69RW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Papanas N, Papatheodorou K, Papazoglou D, Monastiriotis C, Christakidis D, Maltezos E. A comparison of the new indicator test for sudomotor function (Neuropad) with the vibration perception threshold and the clinical examination in the diagnosis of peripheral neuropathy in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2008 Feb;116(2):135-8. Epub 2007 Dec 20.</citation>
    <PMID>18095233</PMID>
  </results_reference>
  <results_reference>
    <citation>Papanas N, Papatheodorou K, Christakidis D, Papazoglou D, Giassakis G, Piperidou H, Monastiriotis C, Maltezos E. Evaluation of a new indicator test for sudomotor function (Neuropad) in the diagnosis of peripheral neuropathy in type 2 diabetic patients. Exp Clin Endocrinol Diabetes. 2005 Apr;113(4):195-8.</citation>
    <PMID>15891953</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>May 6, 2009</study_first_submitted>
  <study_first_submitted_qc>May 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2009</study_first_posted>
  <last_update_submitted>November 25, 2013</last_update_submitted>
  <last_update_submitted_qc>November 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tameside Hospital NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Dr Edward Jude</investigator_full_name>
    <investigator_title>Consultant Physician</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Diabetic neuropathy</keyword>
  <keyword>neuropad</keyword>
  <keyword>Painless peripheral diabetic neuropathy</keyword>
  <keyword>Painful peripheral diabetic neuropathy</keyword>
  <keyword>Autonomic peripheral neuropathy</keyword>
  <keyword>Charcot neuroarthropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

